# AnaptysBio Inc. (ANAB) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $47.73, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). AnaptysBio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.12**. A PEG of 0.12 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.1×**. Each dollar of revenue is priced at 6.1×.
- **Price / book: 134.1×**. The shares trade at 134.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 0.3%** (5-yr avg -20.4%). Free cash flow equals 0.3% of the market value, above its five-year average of -20.4%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: 17.6%**. 17.6% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: -5.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -35.6%**. Return on equity is negative because earnings are negative.
- **Return on assets: -7.4%**. Each dollar of assets produces -7.4% of profit.

## Growth
- **Revenue growth (1 yr): 157.0%** (3-yr 183.6%/yr, 5-yr 25.6%/yr). Revenue grew 157.0% over the last year, against 25.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 91.1%**. Earnings per share rose 91.1%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 9.07** (quick 9.07). Current assets cover the next year's liabilities 9.07 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. AnaptysBio Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover AnaptysBio Inc.; the consensus is strong_buy, with an average price target of $87.25 (+83% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 92.4%** (YTD 45.1%, 3-mo -12.6%). The shares are up 92.4% over twelve months including dividends.
- **From 52-week high: -34.0%** (136.5% above the low). Trading 34% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 1.01** (volatility 63%). Beta of 1.01 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ANAB · Page: https://foliofundamentals.com/stocks/anab

Not investment advice.